Amgen 2007 Annual Report Download - page 30

Download and view the complete annual report

Please find page 30 of the 2007 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

The following table is a selection of certain of our product candidates by phase of development in our ther-
apeutic areas of focus as of February 27, 2008. Additional product candidate (pipeline) information can be found
on our website at (http://www.amgen.com). (This website address is not intended to function as a hyperlink, and
the information contained on our website is not intended to be a part of this filing.)
Molecule Disease/Condition Therapeutic Area
Phase 3 Programs
Cinacalcet HCl Cardiovascular disease in patients with secondary hyperparathyroidism and chronic
kidney disease undergoing maintenance dialysis
Metabolic Disorders
Darbepoetin alfa Patients with chronic kidney disease, anemia and type 2 diabetes General Medicine
Darbepoetin alfa Anemia in heart failure General Medicine
Denosumab Prevention of cancer-related bone damage in breast cancer, prostate cancer and solid
tumors
Oncology
Denosumab Prevention of bone metastases Oncology
Denosumab Bone loss induced by hormone ablation therapy in breast cancer or prostate cancer Oncology
Denosumab Postmenopausal osteoporosis Bone
Motesanib diphosphate First-line non-small cell lung cancer Oncology
Panitumumab First- and second-line colorectal cancer Oncology
Panitumumab Head and neck cancer Oncology
Romiplostim* Immune thrombocytopenic purpura Oncology
Phase 2 Programs
AMG 102 Various cancer types Oncology
AMG 108 Rheumatoid arthritis Inflammation
AMG 222 Type 2 diabetes Metabolic Disorders
AMG 223 Hyperphosphatemia General Medicine
AMG 317 Asthma Inflammation
AMG 386 Various cancer types Oncology
AMG 479 Various cancer types Oncology
AMG 655 Various cancer types Oncology
Cinacalcet HCl Primary hyperparathyroidism Metabolic Disorders
Denosumab Rheumatoid arthritis Inflammation
Denosumab Multiple myeloma Oncology
Motesanib diphosphate First-line breast cancer Oncology
Motesanib diphosphate Thyroid cancer Oncology
Panitumumab Locally advanced head and neck cancer Oncology
rhApo2L/TRAIL Various cancer types Oncology
Romiplostim* Chemotherapy-induced thrombocytopenia in non-small cell lung cancer and lymphoma Oncology
Romiplostim* Myelodysplastic syndromes Oncology
Phase 1 Programs
AMG 221 Type 2 diabetes Metabolic Disorders
AMG 379 Pain Neuroscience
AMG 477 Type 2 diabetes Metabolic Disorders
AMG 557 Systemic lupus erythematosus Inflammation
AMG 714 Psoriasis Inflammation
AMG 745 Muscle wasting disorders General Medicine
AMG 811 Systemic lupus erythematosus Inflammation
AMG 827 Rheumatoid arthritis Inflammation
AMG 853 Asthma Inflammation
Sclerostin Ab (AMG 785) Bone loss Bone
* Program previously identified as AMG 531.
Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.
Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the dis-
ease or condition under study.
Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or
condition under study.
18